Articles On Neurotech International (ASX:NTI)

Neurotech International (NTI) reports 93 per cent of patients showed symptom improvements in a recent trial of its NTI64 drug designed to treat children with ASD Under the trial, 14 patients aged eight to 17 received varying doses of NTI16...

MGC Pharma to go Phase 2 on COVID-19 in South Africa Neurotech says cannabis strain works well in children with Autism Spectrum Disorder Nova Eye’s revenue impacted by China lockdowns MGC Pharma set to start Phase IIb trial in South Afric...

Neurotech has released promising results from a world first study of a medicinal cannabis product in children which could prove to be a game-changer in autism treatment. Neurotech International (ASX:NTI) has released promising results from...

The ASX 200 and XEC small cap indices rise Attention turns to Tuesday’s date with RBA destiny Celsius Resources is hot   The ASX 200 and the Emerging Markets (XEC) indices are both trading higher on Monday up about 1.2%, ahead of tomorrow...

A medical dilemma in its own right – the modern treatment of the condition commonly known as ‘autism’ can come at a high cost and with debilitating side effects – something ASX-listed  Neurotech International aims to change. Developing a r...

A Thai university says adding cannabis to chicken feed has positive results on meat and egg quality Aussie cannabis campaigner now a Member of the Order of Australia MGC Pharma’s CBD treatment proves effective against brain tumors   Chian...

Neurotech International (ASX:NTI) has reported positive preclinical research demonstrating that its NTI164 can improve diclofenac efficacy at low doses.

Neurotech International’s (NTI) preclinical research demonstrates its proprietary cannabis strain can improve Diclofenac efficacy at low doses When combined with Neurotech’s NTI164, Diclofenac showed a 93 per cent reduction in the expressi...

Neurotech says its cannabis strain NTI164 demonstrates strong results when combined with Diclofenac Memphasys prepares for a pre-submission meeting with the US FDA for its sperm separation tech, the Felix System Neurotech reports positive...

ShareCafeWebinar Recap – NTI, MHK, RPM & ESK Catch up on the full webinar with presentations from Neurotech International (ASX: NTI), Metal Hawk (ASX: MHK), RPM Automotive Group (ASX: RPM) & Etherstack (ASX: ESK) Webinar Recap – NT...

ShareCafeNeurotech International (ASX: NTI) – Webinar Presentation Dr. Alexandra Andrews – CEO – Neurotech International Limited is a medical device and solutions company conducting clinical studies to assess the neuro-protective, anti-inf...

Actor Woody Harrelson has opened a cannabis store in West Hollywood Releaf has plans for a weed wellness retreat in Byron Bay Incannex wants to buy out APIRx   It’s not surprising that Woody Harrelson loves weed – the actor was actually...

Kiwi medical device company TruScreen (ASX:TRU) surged 15% this morning after releasing the results of its successful clinical trial in China. The study was conducted alongside the Chinese Obstetricians and Gynaecologists Association (COGA)...

V-Con is Stockhead’s investing focused video conference series, bringing you expert insights, panel discussions and presentations from leading analysts, listed small caps and industry players. Global cannabis sales could hit $35 billion in...

Neurotech International (NTI) appoints Alexandra Andrews as Chief Executive Officer (CEO), effective from Tuesday, next week Dr Andrews has experience in corporate development, investor engagement, product development and commercialisation...

The ASX 200 Health Index (XHJ) is trading lower by 0.30% at the time of writing, compared to the broader index which is up by 0.90%. Regenerative medicine company, Avita Medical (ASX:AVH), has been awarded a purchasing contract from Premier...

Neurotech International (ASX:NTI) says preclinical studies demonstrate that NTI164 can improve the efficacy of prednisone at low doses.

The ASX 200 was unable to break free from its recent shackles, edging lower by 0.11% in the Wednesday session. But as a measure of a little more risk-on sentiment creeping back into markets, the microcap Emerging Markets index comfortably o...

Minerals260 (ASX:MI6), a spinoff from Liontown Resources (ASX:LTR), enjoyed a positive debut despite the ASX finishing down again. The ASX 200 retreated 0.26% to close at 7,821 points with all sectors in the red except consumer staples and...

ShareCafeHidden Gems Webinar Recap – NAOS Asset Management, MMM, NTI & ACW Catch up on the full webinar with a keynote presentation from NAOS Asset Management & presentations from Marley Spoon (ASX: MMM), Neurotech (ASX: NTI) &amp...

Results demonstrated the ability of Neurotech’s NTI/Dolce strains to suppress COX-2 – the main enzyme that causes inflammation in multiple sclerosis patients. Clinical-stage medicinal cannabis company Neurotech International (ASX:NTI) conti...

The results give NTI further momentum as it pursues an expanded development pathway for its proprietary medicinal cannabis treatment. Medical company Neurotech International (ASX:NTI) has announced an important new update in the development...

Neurotech International Limited (ASX:NTI) has announced the continuation of its pre-clinical program in neuro-inflammatory disease models in-line with its research and development pathway. Initial in vitro studies were carried out in collab...

Neurotech International (ASX:NTI) has announced that Professor Allan Cripps AO has been appointed as a non-executive director.

The federal government’s “patent box” initiative caught the eye of Australia’s biotech sector in Tuesday night’s Budget. Speaking with Stockhead, a number of ASX biotechs were broadly positive about the announcement. However, some industry...

Neurotech International (ASX:NTI) has announced the commencement of a phase 1/2 open-label clinical study in 20 children aged between 5-17 years with Autism Spectrum Disorder.

Summary Neurotech International has commenced Phase I/II open-label clinical trial in children having Autism Spectrum Disorder. Multinational pharmaceutical company AFT Pharmaceuticals disclosed the extension of licensing of Maxigesic®...

Neurotech International Limited (ASX:NTI) has commenced a Phase I/II open label clinical study in 20 children aged between 5-17 years with Autism Spectrum Disorder (ASD). This much-anticipated study is being conducted under the guidance and...

The company’s preparations over the last quarter means that it is now ready to conduct Phase I and II studies on its medicinal cannabis for autistic children. Neurotech International (ASX:NTI) has released an update on its quarterly activit...

The capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the first four months of the year. Across 325 deals, ASX companies have raised $9.878 billion in capital amidst IPOs, placements and rights issues....

ASX pot stocks have run hot in recent months but eight in particular have been particularly rewarding for shareholders. Many pot stocks ran cold prior to COVID-19 as regulatory progress stalled and global markets didn’t take off. Australia...

Australia’s medical marijuana industry is showing strong growth, according to an industry-leading biannual report. The Freshleaf Analytics report, released this morning, says that patient numbers have grown 15-fold over the past two and a h...

Neurotech International Limited (ASX:NTI) has announced a strategic cultivation partnership with CannaPacific Limited to grow and maintain genetic stock and assist in the development of elite varietal strains through their exclusive licenci...

Neurotech International Limited (ASX:NTI) has expanded its exclusive license with Dolce Cann Global Pty Ltd to now include all neurological disorders, disease or affliction affecting the human brain function, specifically - Autism, Epilepsy...

Neurotech International Limited (ASX:NTI) has provided an update on its clinical study program. As we reported in late December, Neurotech successfully completed a series of in vitro studies that demonstrated that the NTI/Dolce strains, wit...

Neurotech International Limited (ASX:NTI) has provided a comprehensive overview and update regarding the company’s cannabis strains, development strategy and some of the key near-term objectives expected to be delivered. Neurotech is a medi...

Neurotech International Ltd (ASX:NTI) has today confirmed the successful completion of in-vitro studies using human brain cells to assess and validate the anti-inflammatory and neuro-modulatory properties of its proprietary DOLCE/NTI cannab...

–The below is a company sponsored announcement– ASX cannabis stocks are gaining momentum, stimulated by significant developments in the global regulatory environments in recent months. On the cusp of a potential rerate is $29M capped Neur...

The last month has been an extremely rewarding period for Neurotech International Limited (ASX:NTI) with the company commencing stage 1 clinical product formulation and development studies in mid-November with a view to entering into clinic...

Special Report: Neurotech International (ASX:NTI) says laboratory tests have confirmed the neuro-protective, anti-inflammatory and neuro-modulatory activities of seven special cannabis ... Read More The post Lab tests confirm neuro-protecti...

ShareCafeHidden Gems Webinar Recap – NTI, RLG, 3DP, EMV Catch up on the full webinar with presentations from EMVision (ASX:EMV), Pointerra (ASX:3DP), Roolife Group (ASX:RLG) and Neurotech International (ASX: NTI). Hidden Gems Webinar Recap...

ShareCafeNeurotech International (ASX: NTI) – Hidden Gems Webinar Presentation Presenter – Brian Leedman – Chairman – Neurotech international limited, or Nurotech is a medical device and solutions company incorporated in Australia, operati...

Special Report: Neurotech International (ASX:NTI) has a new chairman and a new focus – cannabis treatments for cognitive disorders, rather ... Read More The post Neurotech gets new chairman, makes pivot to cannabis space official appeared f...

Special Report: Austism treatment specialist Neurotech International says unique strains of cannabis it has obtained may hold the key to ... Read More The post Neurotech’s unique cannabis strains may be better than CBD appeared first on Sto...

A quick wrap of the ASX’s key winners and losers on Friday, August 21. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 830 stocks rose, 552 declined and 7...

A quick wrap of the ASX’s key winners and losers on Tuesday, August 18. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 888 stocks rose, 534 declined and...

A quick wrap of the ASX’s key winners and losers on Wednesday, July 22. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 630 stocks rose, 765 declined and...

A quick wrap of the ASX’s key winners and losers on Tuesday, July 21. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potentially market-moving announcements during the day. Today 1032 ASX stocks rose, 38...

A quick wrap of the key winners and losers on Monday, July 6. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 712 stocks rose, 576 declined and 819 were u...

Neurotech International (ASX: NTI) has collared an exclusive global licence to use Dolce Cann Global’s cannabis strains to treat autism, epilepsy and ADHD. Dolce is an Australian based medicinal cannabis company that has created proprietary...